7 Result(s)

Article

Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study

Rapid global approval of coronavirus disease 2019 (COVID-19) vaccines and concurrent introduction in high-income countries and low- and middle-income countries (LMIC) highlights the importance of equitable saf...

Comfort K. Ogar, Jonathan Quick, Hannah N. Gilbert, Rick A. Vreman… in Drug Safety (2023)

Article

Comment on “Deterministic Sensitivity Analysis Under Ignorance”

Rick A. Vreman, Joost W Geenen, Saskia Knies… in PharmacoEconomics (2021)

Article

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods

Deterministic sensitivity analyses (DSA) remain important to interpret the effect of uncertainties in individual parameters on results of cost-effectiveness analyses. Classic DSA methodologies may lead to wron...

Rick A. Vreman, Joost W. Geenen, Saskia Knies… in PharmacoEconomics (2021)

Article

Increasing the information provided by probabilistic sensitivity analysis: The relative density plot

Results of probabilistic sensitivity analyses (PSA) are frequently visualized as a scatterplot, which is limited through overdrawing and a lack of insight in relative density. To overcome these limitations, we...

Joost W. Geenen, Rick A. Vreman… in Cost Effectiveness and Resource Allocation (2020)

Article

A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics

High budget impact (BI) estimates of new drugs have led to decision-making challenges potentially resulting in restrictions in patient access. However, current BI predictions are rather inaccurate and short te...

Joost W. Geenen, Svetlana V. Belitser… in The European Journal of Health Economics (2020)

Article

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia

The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assess...

Rick A. Vreman, Joost W. Geenen… in Applied Health Economics and Health Policy (2019)